Preliminary regulatory assessment obtained for Metvix® photodynamic therapy for treatment of actinic keratosis
Oslo 29th november 2000PhotoCure ASA submitted its first marketing authorisation application for Metvix® photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) to the Swedish regulatory authorities (MPA) in May of this year. As part of the overall review process, the MPA has now given its initial response to the file provided by PhotoCure in its marketing application. As is normal, the MPA has asked PhotoCure to clarify certain points which have been raised during its review of the Metvix® PDT documentation.Vidar Hansson, President and CEO, commenting on the response from